Literature DB >> 20503018

Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option?

Marcus D Säemann1, Michael Krebs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20503018     DOI： 10.1007/s00508-010-1369-2

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  37 in total

1.  The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events.

Authors:  J Hjelmesaeth; A Hartmann; T Leivestad; H Holdaas; S Sagedal; M Olstad; T Jenssen
Journal:  Kidney Int       Date:  2006-02       Impact factor: 10.612

2.  New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation.

Authors:  Fernando G Cosio; Yogish Kudva; Marije van der Velde; Timothy S Larson; Stephen C Textor; Matthew D Griffin; Mark D Stegall
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

Review 3.  Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.

Authors:  Pantelis A Sarafidis; Panagiotis C Stafylas; Panagiotis I Georgianos; Athanasios N Saratzis; Anastasios N Lasaridis
Journal:  Am J Kidney Dis       Date:  2010-01-29       Impact factor: 8.860

4.  Thiazolidinediones and fractures in men and women.

Authors:  Colin R Dormuth; Greg Carney; Bruce Carleton; Ken Bassett; James M Wright
Journal:  Arch Intern Med       Date:  2009-08-10

5.  Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.

Authors:  Mandeep Bajaj; Rais Baig; Swangjit Suraamornkul; Lou Jean Hardies; Dawn K Coletta; Gary W Cline; Adriana Monroy; Shailja Koul; Apiradee Sriwijitkamol; Nicolas Musi; Gerald I Shulman; Ralph A DeFronzo
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

Review 6.  Thiazolidinediones: metabolic actions in vitro.

Authors:  C Fürnsinn; W Waldhäusl
Journal:  Diabetologia       Date:  2002-07-05       Impact factor: 10.122

7.  Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.

Authors:  Hongyu Zhang; Jharna Saha; Jaeman Byun; MaryLee Schin; Matthew Lorenz; Robert T Kennedy; Matthias Kretzler; Eva L Feldman; Subramaniam Pennathur; Frank C Brosius
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-30

8.  Rosiglitazone is associated with mortality in chronic hemodialysis patients.

Authors:  Sylvia P B Ramirez; Justin M Albert; Margaret J Blayney; Francesca Tentori; David A Goodkin; Robert A Wolfe; Eric W Young; George R Bailie; Ronald L Pisoni; Friedrich K Port
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

9.  Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression.

Authors:  Cristianne Alexandre da Silva; Ana Carolina de Bragança; Maria Heloísa Massola Shimizu; Talita Rojas Sanches; Maria Angela Zanella Fortes; Ricardo Rodrigues Giorgi; Lúcia Andrade; Antonio Carlos Seguro
Journal:  Am J Physiol Renal Physiol       Date:  2009-08-05

10.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321
View more
  1 in total

Review 1.  Diabetes Mellitus Following Renal Transplantation: Clinical and Pharmacological Considerations for the Elderly Patient.

Authors:  David Langsford; Adam Steinberg; Karen M Dwyer
Journal:  Drugs Aging       Date:  2017-08       Impact factor: 4.271
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.